1[1] Perucca E.A pharmacological and clinical review of topiramate,a new antiepileptic drug[J].Pharmacol Res,1997,35(4):241.
2[2] Britton JW,So EL.New antiepileptic drugs:prospects for the future[J].J Epilepsy,1995,8:267.
3[3] Privitera MD.Topiramate:a new antiepileptic drug[J].Ann Pharmacother,1997,31(10):1164.
4[4] Doose DR,Walker SA,Gisclon LG,et al.Single-dose pharmacokineics and effect of food on the bioavailability of topiramate,a novel antiepilepticdrug[J].J Clin Pharmacol,1996,36:884.
5[5] Perucca E,Bialer M.The clinical pharmacokinetics of the mewer antiepileptic drug:focus on topiramate,zonisamide and tiagabine[J].Clin Pharmacokinet,1996,31:29.
6[6] Shorvon SD.Safety to topiramate:adverse events and relationships to dosing[J].Epilepsia,1996,37(Suppl 2):s18.
7[7] Bourgeois BF.Drug interaction profile of topiramate[J].Epilepsia,1996,37(Suppl 2):s14.
8[8] Tartara A,Sartori I,Manni R,et al.Efficacy and safety of topiramate in refratory epilepsy:a long-term prospective trial[J].Ital J Neurol Sci,1996,17:429.
9[9] Markind JE.Topiramate:a new antiepileptic drug[J].Am J Health Syst Pharm,1998,55(6):554.
同被引文献16
1Doose DR,Gisclon LG, Stellar SM, et al. The effect of food on the bioavailability of topiramate from 100-and 400-mg tablets in healthy male subjects[J]. Epilepsia, 1992;33:105
2Gisclon LG,Curtin CR,Kramer LD. The steady-state(ss)pharmacokinetics(pk) of phenytoin of (Dilantin) and topiramate (Topamax) in topiramate in epleptic patients on monotherapy,and during combination therapy[J]. Epilepsia, 1994;35:54
3Sachdeo RC,Sachdeo SK,Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy[J]. Epilepsia, 1996;37:774-80
4Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and comcomitant therapy[J]. Epilepsia, 1997;38(3):324-33
5Johnnessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs[J]. Epilepsia, 1997; 38: S18-S23
6Doose DR,Rosenfeld WE,Schaefer P, et al. Evaluation of the potential pharmacokinetic interaction between topiramate and the oral contraceptive combination norethin drone/ethinyl estradiol[J]. J Clin pharmacol, 1995;34:1031
7Takeoka M, Homles GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy[J]. Epilepsia, 2001;42):387-92
8Shank RP,Gardocki JF,Vaught JL, et al. Topiramate:preclinical evaluation of a structurally novel anticonvulsant[J]. Epilepsia, 1994;35:450-60
9Rosenfeld WE,Doose DR,Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy[J]. Pediatr Neurol, 1999; 20:339-44
10Gisclon LG, Riffits JM, Sica DA, et al. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function[J]. Pharm Res, 1993;10:S397
